Selected Publications
Landsburg DJ, Morrissette JJ, Nasta SD, Barta SK, Schuster SJ, Svoboda J, Chong EA, Bagg A.: TP53 mutations predict for poor outcomes in patients with newly-diagnosed aggressive B cell lymphomas in the current era Blood Adv : 2023.
Landsburg DJ, Nasta SD, Svoboda J, Gerson JN, Schuster SJ, Barta SK, Chong EA, Difilippo H, Weber E, Cunningham K, Catania C, Garfall AL, Stadtmauer EA, Frey NV, Porter DL.: Survival outcomes for patients with relapsed/refractory aggressive B cell lymphomas following receipt of high dose chemotherapy/autologous stem transplantation and/or chimeric antigen receptor-modified T cells Transplant Cell Ther : 2023.
Landsburg DJ, Morrissette JJD, Schuster SJ, Nasta SD, Gerson JN, Barta SK, Svoboda J, Chong EA, Lim MS.: Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas Oncotarget 13 : 1237-1244,2022.
Landsburg DJ, Nasta SD, Gerson JN, Svoboda J, Chong EA, Schuster SJ, Barta SK, Robinson KW, Hughes ME.: Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy Leuk Lymphoma : 2021.
Landsburg DJ, Barta SK, Ramchandren R, Batlevi C, Iyer S, Kelly K, Micallef IN, Smith SM, Stevens DA, Alvarez M, Califano A, Shen Y, Bosker G, Parker J, Soikes R, Martinez E, von Roemeling R, Martell RE, Oki Y.: Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses Br J Haematol : 2021.
Landsburg, D. J., Koike, A., Nasta, S. D., Svoboda, J., Schuster, S. J., Wasik, M. A., Caponetti, G. C.: Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas Cancer Immunol Immunother : 2020.
Ayers, E. C., Margolis, D., Landsburg, D. J.: Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies Clin Lymphoma Myeloma Leuk : 2020.
Frosch, Z. A. K., Landsburg, D. J.: Molecular Risk Stratification in Aggressive B-Cell Lymphomas J Clin Oncol 38 (18): 2014-2017,2020.
Landsburg, D. J., Ayers, E. C., Bond, D. A., Maddocks, K. J., Karmali, R., Behdad, A., Curry, M., Wagner-Johnston, N. D., Modi, D., Ramchandren, R., Assouline, S. E., Faramand, R., Chavez, J. C., Torka, P., Mier Hicks, A., Medeiros, L. J., Li, S.: Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy Br J Haematol 189 (2): 313-317,2020.
Ayers, E. C., Li, S., Medeiros, L. J., Bond, D. A., Maddocks, K. J., Torka, P., Mier Hicks, A., Curry, M., Wagner-Johnston, N. D., Karmali, R., Behdad, A., Fakhri, B., Kahl, B. S., Churnetski, M. C., Cohen, J. B., Reddy, N. M., Modi, D., Ramchandren, R., Howlett, C., Leslie, L. A., Cytryn, S., Diefenbach, C. S., Faramand, R., Chavez, J. C., Olszewski, A. J., Liu, Y., Barta, S. K., Mukhija, D., Hill, B. T., Ma, H., Amengual, J. E., Nathan, S., Assouline, S. E., Orellana-Noia, V. M., Portell, C. A., Chandar, A., David, K. A., Giri, A., Hess, B. T., Landsburg, D. J.: Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure Cancer 126 (2): 293-303,2020.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-182
3400 Civic Center Boulevard
Philadelphia,
PA
19104
Phone: 215-615-7361
Patient appointments: 800-789-7366